Bipolar Disorder – Epidemiology Insights and Disease Burden Report – 2020 To 2040
- Published Date : November 6, 2025
- Updated On : June 23, 2026
- Pages : 52
Bipolar Disorder Epidemiology Insights and Disease Burden
Thelansis’s “Bipolar Disorder Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Bipolar Disorder Overview
Bipolar disorder is a chronic mood condition marked by cycling episodes of depression and mania or hypomania that require ongoing management rather than a one-time intervention, with treatment typically combining mood-stabilizing or antipsychotic medication with structured psychosocial support to reduce the frequency and severity of episode recurrence. Much of the recent movement in the field has come not from an entirely new drug mechanism but from an expanding menu of antipsychotic options and improved ways of delivering long-established treatments, including new formulations designed to smooth out symptom control, reduce dosing burden, and better manage acute agitation without more invasive interventions. At the same time, one of the field’s oldest and most effective treatments, lithium, continues to be limited by its narrow safety margin, prompting renewed interest in reformulating how it is delivered rather than replacing it outright. Beyond incremental improvements to existing drug classes, earlier-stage research is exploring novel approaches, including psychedelic compounds and ketamine based therapies for depressive episodes that do not respond to standard treatment.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
Bipolar Disorder Epidemiology Insights and Disease Burden
Thelansis’s “Bipolar Disorder Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Bipolar Disorder Overview
Bipolar disorder is a chronic mood condition marked by cycling episodes of depression and mania or hypomania that require ongoing management rather than a one-time intervention, with treatment typically combining mood-stabilizing or antipsychotic medication with structured psychosocial support to reduce the frequency and severity of episode recurrence. Much of the recent movement in the field has come not from an entirely new drug mechanism but from an expanding menu of antipsychotic options and improved ways of delivering long-established treatments, including new formulations designed to smooth out symptom control, reduce dosing burden, and better manage acute agitation without more invasive interventions. At the same time, one of the field’s oldest and most effective treatments, lithium, continues to be limited by its narrow safety margin, prompting renewed interest in reformulating how it is delivered rather than replacing it outright. Beyond incremental improvements to existing drug classes, earlier-stage research is exploring novel approaches, including psychedelic compounds and ketamine based therapies for depressive episodes that do not respond to standard treatment.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)